IA or PE - What is the Best Treatment Option of Steroid Refractory Neu
Immunoadsorption or Plasma Exchange - What is the Best Treatment Option of Steroid Refractory Neurological Autoimmune Diseases
What it found
We found no results in the registry or in papers.
This trial finished 7 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Apheresis therapy by Octo Nova Technology (DIAMED, Cologne, Germany)
What it measured
Main measures
Change in descriptive characterization of Symptoms
After 7 days. Symptoms were assessed at baseline before the first intervention (day 1) and immediately after the last intervention (day 7).]
Change in the "Expanded Disability Status Scale" (EDSS)
After 7 days. EDSS were assessed at baseline before the first intervention (day 1) and immediately after the last intervention (day 7).
Disability progression
Other measures (2)
Change in concentration of Immunglobulins
After 7 days. Immunglobulins were measured before and after the first intervention (day 1) and immediately before after the last intervention (day 7).
Change in concentration of human cytokines
After 7 days. Cytokines were measured before and after the first intervention (day 1) and immediately before and after the last intervention (day 7).
Blood or spinal fluid markersImmune response
Who could take part
MS (type not specified) · 18 to 80
Show the full criteria
Inclusion criteria
* autoimmune neurological therapy refractory disease
Exclusion criteria
* Intake of Angiotensin-converting-enzyme inhibitors (ACE inhibitors) because of allergic reactions by using tryptophan adsorber * contraindication for any anticoagulation * contraindication for treatment with citrate dextrose anticoagulation
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
In this prospective controlled monocentric observational study, we assessed safety and efficacy of therapy with IA or PE in patients with neurological autoimmune diseases. In the subgroup analysis of MS patients also the EDSS was evaluated. In addition, we investigated possible pathomechanisms, such as cytokine alterations under therapy.
Loading reviews and guidelines…
History
Started
Jun 2016
Main results due
Sept 2019
Finished
Dec 2019